glp 1 and gallstones Gastrointestinal safety of incretin therapies: are we there yet? Study Finds Diabetic Patients on

Explore Mitopures role in muscle health and Ozempic face. What to know GLP-1 inhibitors are a new class of weight loss medications offering a powerful way to support people struggling with weight

Gaining momentum Lilly has gained sales momentum in head-to-head competition with Novo Nordisk to bring to market GLP-1 drugs for obesity and diabetesled by tirzepatide, marketed for adult type 2 diabetes as Mounjaro and for obesity as Zepbound

Gastrointestinal losses can result in hypokalaemia, which may manifest as muscle weakness, cramps, cardiac arrhythmias, and constipation

Mounjaro costs approximately $1,023, while Wegovy is the most expensive at $1,349

It has therefore been postulated that the administration of molecules capable of mimicking the action of GLP-1 and/or GIP could reproduce this incretin effect and thus stimulate insulin production and improve glycemic control in type 2 diabetics